Falk Gastro Review Journal

Current science, compiled for you from the multitude of scientific publications – this is the Falk Gastro Review Journal.

Dunkel- bis hellblaue Grafik einer Tonspur-Frequenz auf orangem Hintergund.

The latest issues

Edition 2/2024

Edition 1/2024

Edition 4/2023

Find here all FGR publications since mid-2022 selected and reviewed from international medical journals. Click here above to browse the individual quarterly issues or use the filters below or click chronologically through all articles.

All articles

Endoscopic vacuum therapy for upper gastrointestinal leaks and perforations: Analysis from a multicenter Spanish registry

Am J Gastroenterol. 2023;118(10):1797–806

The carbon footprint of ambulatory gastrointestinal endoscopy

Endoscopy. 2023;55(10):918–26

Efficacy of probiotics in irritable bowel syndrome: Systematic review and meta-analysis

Gastroenterology. 2023;165(5):1206-18

Early ileocecal resection for Crohn’s disease is associated with improved long-term outcomes compared with anti-tumor necrosis factor therapy: A population-based cohort study

Gastroenterology. 2023;165(4):976–85.e3

Adalimumab in biologic-naive patients with Crohn’s disease after resolution of an intra-abdominal abscess: A prospective study from the GETAID

Clin Gastroenterol Hepatol. 2023;21(13):3365–78.e5

Real-world comparative effectiveness of ustekinumab vs. anti-TNF in Crohn’s disease with propensity score adjustment: Induction phase results from the prospective, observational RUN-CD study

Inflamm Bowel Dis. 2023;29(11):1741–50

Higher intra-abdominal visceral adipose tissue mass is associated with lower rates of clinical and endoscopic remission in patients with inflammatory bowel diseases initiating biologic therapy: Results of the constellation study

Gastroenterology. 2023;165(4):963–75.e5

Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8-week induction therapy (U-ACHIEVE Maintenance): Overall results from the randomized, placebo-controlled, double-blind, phase 3 maintenance study

Lancet Gastroenterol Hepatol. 2023;8(11):976–89

Delayed ustekinumab responders in ulcerative colitis have greater inflammatory burden but similar outcomes as early responders

Clin Gastroenterol Hepatol. 2023;21(13):3387–96.e1